Curative Health Services

Curative Biotechnology ("Curative Biotech") develops novel therapies primarily targeting rare diseases. Its lead focus area as of 2024–2025 has been degenerative eye disorders through an exclusive license with the National Eye Institute at NIH. Other ongoing programs address infectious disease and neuro-oncology. The company operates a flexible business model that identifies, acquires/inlicenses, and advances promising assets—often aiming to partner or outlicense after achieving key clinical milestones rather than commercializing independently. It leverages outsourced expertise across drug development stages to accelerate progress while minimizing costs.